Cambridge Investment Research Advisors
KNSA icon

Cambridge Investment Research Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Cambridge Investment Research Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$332K Buy
+5,184
New +$269K ﹤0.01% 3118

Other funds holding KNSA

New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
FEG
Financial Enhancement Group Anderson, Indiana $839M AUM 18.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
JWS
Juncture Wealth Strategies Scottsdale, Arizona $384M AUM 27.62% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Cambridge Investment Research Advisors's KNSA Position: Q2 2026 in Review

Cambridge Investment Research Advisors opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q2 2026: 5,184 shares worth $332K. The stake represents ﹤0.01% of the portfolio and ranks #3118 among its holdings.

46 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Cambridge Investment Research Advisors held 5,184 shares of Kiniksa Pharmaceuticals worth $332K as of Q2 2026.
  • Kiniksa Pharmaceuticals was a new Cambridge Investment Research Advisors position in Q2 2026.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3118 holding.
  • 46 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.